Skip to Content
  • Thoughts on Reproducibility

    Not too long ago, I was talking to someone outside the field about the “reproducibility crisis”. They’d heard that there were many published p… Read More
  • Neurotrope: A Shameful PR Stunt

    There was some Alzheimer’s news the other day, but it wasn’t actually about Alzheimer’s. Not very much. It was more about hype, press releases… Read More
  • Lose Money Now! Ask Me How!

    Some readers will remember some odd moves in small biotechs like Galena Biosciences, Cytrx, and Lion Biotechnologies, among others. It can be hard to keep track… Read More
  • The Predatory Beat Goes On

    I’m not the least bit surprised by this effort. The predatory junk journals will do what ever they can think of to bring in customers and cash, with no re… Read More
  • Marathon’s Real Costs

    Endpoints has done a great breakdown on the actual costs that Marathon Pharmaceuticals is likely to have incurred while bringing their wildly overpriced old gen… Read More
  • The Case of Marathon Pharmaceuticals

    So since drug pricing and FDA regulations are so much in the news, it would seem like the perfect time for a small company to game the system for big profits, r… Read More
  • Not Quite What Friends Are For

    Folks who do industrial drug research know that they’re around proprietary information, and they generally know to keep quiet about it. That can be a bit… Read More
  • Be Sure The Funds Are Deposited

    I’ve written before here about the many people who are convinced that most (or all) diseases have to do with the body’s pH – most often, you h… Read More
Page 1 of 2312345...1020...Last »